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Genome-wide Analyses Identify KIF5A as a Novel ALS Gene 
 
 
SUMMARY 
To identify novel genes associated with ALS, we undertook two lines of investigation. 
We carried out a genome-wide association study comparing 20,806 ALS cases and 
59,804 controls. Independently, we performed a rare variant burden analysis comparing 
1,138 index familial ALS cases and 19,494 controls. Through both approaches, we 
identified kinesin family member 5A (KIF5A) as a novel gene associated with ALS.  
Interestingly, mutations predominantly in the N-terminal motor domain of KIF5A are 
causative for two neurodegenerative diseases, hereditary spastic paraplegia (SPG10) and 
Charcot-Marie-Tooth Type 2 (CMT2). In contrast, ALS associated mutations are 
primarily located at the C-terminal cargo-binding tail domain and patients harboring loss 
of function mutations displayed an extended survival relative to typical ALS cases. Taken 
together, these results broaden the spectrum of subphenotypes resulting from mutations in 
KIF5A and strengthen the role of cytoskeletal defects in the pathogenesis of ALS.  
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INTRODUCTION 
Amyotrophic lateral sclerosis (ALS, OMIM #105400) is a neurodegenerative disorder 
clinically characterized by rapidly progressive muscle weakness and death due to 
respiratory failure, typically within two to four years of symptom onset (van Es et al., 
2017). Although ALS is perceived as being rare, approximately 6,000 Americans die 
annually from the condition (Hirtz et al., 2007). Furthermore, the number of ALS cases 
across the globe will increase to nearly 400,000 in 2040, predominantly due to aging of 
the population (Arthur et al., 2016). This increase is anticipated to place an enormous 
socioeconomic burden on global healthcare systems, in particular because the annual 
healthcare cost per patient with ALS is among the highest for any neurological disease 
(Gladman and Zinman, 2015).  
 
Approximately 10% of ALS display a family history (FALS) whereas the remaining 90% 
of ALS cases are sporadic (SALS) in nature. Driven in large part by advances in 
genotyping and sequencing technology, the genetic etiology of two-thirds of familial 
cases and about 10% of sporadic ALS cases is now known (Chia et al., 2017; Renton et 
al., 2014). Mutations in SOD1 were the first identified cause of ALS (Rosen et al., 1993) 
contributing to ~20% of FALS and ~2% of SALS. More recently, pathogenic 
hexanucleotide repeat expansions located within the first intron of the C9orf72 gene on 
chromosome 9p21 were identified as the most common cause of both FALS (~40%) and 
SALS (~7%) (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Interestingly, this 
repeat expansion contributes to ~10% of all FTD cases thus genetically explaining much 
of the overlap between these clinical syndromes (Majounie et al., 2012). As a result of 
 3 
these major discoveries, there are several ongoing efforts towards directed silencing of 
these mutant genes which could result in a therapeutic treatment for up to 10% of all ALS 
cases and for a similar portion of FTD cases.   
 
In addition to the insights provided by each novel ALS gene, the collective knowledge 
gained from genetic factors provides a more comprehensive understanding of the 
interacting pathways underlying motor neuron degeneration. For example, the 
identification of ALS genes has revealed at least three pathways believed to contribute to 
the development of ALS: (1) RNA processing (based on the observation of mutations in 
C9orf72, TDP-43, FUS, and MATR3); (2) protein homeostasis (UBQLN2, VCP, OPTN, 
VAPB); (3) cytoskeletal dynamics (PFN1, TUBA4A, DCTN1)(Robberecht and Eykens, 
2015). Understanding the mechanisms leading to disease pathogenesis again provides 
targets for therapeutic intervention that may be applicable to all forms of ALS.  
 
Due to the decreased accessibility of multiple affected family members with unknown 
genetic etiology, there has been an increased focus on identification of ALS associated 
genes with moderate to low impact. Despite their lower impact, such genes continue to 
provide valuable insight into ALS pathogenesis. For example, the risk factor TBK1 is 
known to interact with the product of ALS associated gene OPTN, further solidifying the 
role of autophagy and protein homeostasis in disease development (Cirulli et al., 2015; 
Freischmidt et al., 2015; Maruyama et al., 2010; Morton et al., 2008). Similarly, the risk 
factor NEK1, identified through a rare variant burden analysis of index FALS, is a known 
binding partner of C21orf2, an ALS risk factor found through GWAS (Cirulli et al., 
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2015; Kenna et al., 2016; Malovannaya et al., 2011; van Rheenen et al., 2016). The 
interaction of these two proteins is required for efficient DNA damage repair (Fang et al., 
2015), a pathway which is becoming increasingly recognized as a contributing factor in 
ALS and other neurodegenerative diseases (Coppedè and Migliore, 2015; Lopez-
Gonzalez et al., 2016; Madabhushi et al., 2014; Wang et al., 2013).  
 
Genome-wide Association Studies Identifies KIF5A as a Novel ALS Associated Gene 
 
To identify new susceptibility loci operating in ALS, we undertook a large-scale genome-
wide association study (GWAS) involving 12,663 patients diagnosed with ALS and 
53,439 control subjects (Table S1, S2). Our data was then incorporated into a meta-
analysis with a recently published GWAS involving 12,577 ALS cases and 23,475 
control subjects (van Rheenen et al., 2016). After imputation and quality-control 
measures (Methods, Figure S1), 10,031,630 genotyped and imputed variants from 
20,806 ALS cases and 59,804 control samples were available for association analysis 
(Figure 1A). Quantile-quantile plots did not show evidence of significant population 
stratification (λ1000 = 1.001, Figure S2). Single nucleotide polymorphisms (SNPs) 
achieving genome-wide significance (P < 5.0x10-8) are listed in Table 1, Table S3 and 
suggestive loci with SNPs associated at P < 5.0×10−7 are listed in Table S4.  
 
Our analysis revealed five previously identified genes that achieved genome-wide 
significance (TNIP1, C9orf72, TBK1, UNC13A, C21orf2)  
(Benyamin et al., 2017; Laaksovirta et al., 2010; Shatunov et al., 2010; van Es et al., 
2009; van Rheenen et al., 2016). In addition, we observed a strong association signal for 
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five SNPs in linkage disequilibrium on chromosome 12q14.1 that reached genome-wide 
statistical significance (Table 1, Figure 1B) spanning a region several hundred kilobases. 
Of the five SNPs, two of them resided in close proximity to each other within a large 
intergenic region and two in proximity to short-chain dehydrogenase/reductase family 9C 
member 7 (SDR9C7), a gene expressed primarily in skin. However, one SNP 
(rs113247976) results in a p.Pro986Leu coding change within the kinesin family member 
5A (KIF5A) gene (P=6.4x10-10 , OR= 1.38, 95% CI, 1.24-1.53). The case:control allele 
frequencies for the combined discovery cohort were 2.07%:1.55% and genotype counts 
were 5/529/12,043:7/786/22,682 (homozygotes alternative 
allele/heterozygotes/homozygous reference allele)(Figure 2). Calculations based on our 
cohort size as well as the OR and allele frequency of rs113247976 result in a ~99.5% 
power to detect this as an ALS associated SNP (Figure S3). 
 
Rare Variant Burden Analysis Identifies KIF5A as an ALS gene  
In an independent line of investigation, we attempted to identify novel ALS genes 
through exome-wide rare variant burden analysis (RVB). In brief, RVB compares the 
frequency of variants within each gene below a user defined frequency threshold in a 
case-control cohort. As the last two ALS associated genes identified by this methodology 
(TBK1, NEK1) displayed an increased frequency of loss of function (LOF) variants, we 
focused our initial analysis on such variants (consisting of nonsense and predicted splice-
altering) (Cirulli et al., 2015; Freischmidt et al., 2015; Kenna et al., 2016).  
 
Towards this end, we performed RVB testing for association of LOF variants in a cohort 
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of 1,138 index FALS cases and 19,494 controls, after applying quality control filters 
(Methods, Figure S4, Table S5). Genes displaying P< 5x10-4 are shown in Table 2. The 
previously identified ALS genes, TBK1 (P=5.58 x 10-7, OR= 15.11, 95%CI = 5.81-38.69) 
and NEK1 (P=1.68 x 10-6, OR= 6.64, 95%CI = 3.32-12.51), yielded strong associations 
with ALS reaching exome-wide significance (Figure 3). In addition, we observed a 
single novel gene reaching exome-wide significance, KIF5A (P=5.55x10-7; OR=32.07, 
95%CI = 9.05-135.27). Within this gene, we observed 6 LOF variants in our 1,138 cases 
(0.53%) compared to 3 such variants in our comparison cohort of 19,494 controls 
(0.015%)(Table 2). There was no evidence of genomic inflation (λ=0.93, Figure S5), 
sequencing center or other sub-cohort bias (Figure S6), or call rate bias (Figure S7) in 
our analysis. Of the index FALS cases carrying KIF5A LOF mutations, we obtained 
DNA from two siblings of the proband carrying a c.2993-3C>T, exon 27 - 5' splice 
junction variant, and from a sibling of a different proband carrying a c.3020+2T>A, exon 
27 - 3' splice junction variant. These variants segregated with disease within each of these 
families.  
 
Interestingly, when we investigated the location of the six ALS associated variants 
present in KIF5A, all occurred within a 34 bp stretch of DNA and were predicted to effect 
splicing of exon 27 that encodes amino acids 998-1007 (Table 3, Figure 4A). Five of the 
six variants were located on sequential base pairs on the 3’ end of the exon, whereas one 
was located 5’ end of the exon. We used the application ASSEDA (Automated Splice 
Site and Exon Definition Analyses) to predict any mutant mRNA splice isoforms 
resulting from these variants (Sheth et al., 2006). This algorithm predicted a complete 
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skipping of exon 27 for all variants, yielding a transcript with a frameshift at coding 
amino acid 998, the deletion of the normal C-terminal 34 amino acids of the cargo-
binding domain, and the extension of an aberrant 39 amino acids to the C-terminus 
(Table 3, Figure 4B, 4C). The presence of transcripts with skipped exon 27 was 
confirmed by performing RT-PCR using RNA from lymphoblasts available for a single 
patient carrying the c.3020+2T>A, exon 27 - 3' splice junction variant and two control 
lines (Figure 4D). Lymphoblasts were not available for any other patient carrying a 
KIF5A LOF variant.  
 
Our initial RVB was restricted to single nucleotide variants due to the limited sensitivity 
and comparatively high false positive rates associated with identifying small insertions 
and deletions (indels) within exome sequencing data (Fang et al., 2014). Based on our 
discovery of increased LOF variants within KIF5A, we re-evaluated this region for the 
presence of indels. Our analysis revealed two (0.026%) indels within our cohort of 1,138 
FALS cases, compared to zero (0%) indels among 19,494 control samples. Both of these 
indels (p.Asp996fs, p.Asn999fs) resulted in a frameshift of the KIF5A protein coding 
sequence, and were located close to the splice junction variants that we previously 
observed to cause skipping of exon 27 resulting in a frameshift at amino acid 998 (Table 
3). Sanger sequencing confirmed the presence of both indels. Combining the results of 
the single nucleotide and indel variant analysis yielded a highly significant P of 3.8x10-9 
(OR=41.16, 95% CI, 12.61-167.57). We failed to detect any signals of RVB association 
for rare missense variants across KIF5A or within any sub-domain of the gene (Table 
S7). 
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Replication Analysis of rs113247976 and LOF Variants in KIF5A 
Given the strong signal of the missense variant identified by our GWAS (p.Pro986Leu, 
rs113247976) and its close proximity to the LOF variants identified by our RVB (amino 
acids 996-999), we attempted to replicate its association with ALS by analyzing 
additional cohorts. To accomplish this, we evaluated this variant in a cohort of 4,160 
ALS cases and 18,650 controls that were non-overlapping with our GWAS discovery 
analysis, after applying quality control filters (Methods, Figure S8). This included non-
overlapping samples from our RVB analysis (673 FALS, 17,696 controls). Analysis of 
the cohort revealed an allele frequency of 1.73% in cases and 1.32% in controls 
(rs113247976, P=1.24x10-3, OR=1.38, 95% CI=1.14-1.66), thereby replicating the 
association of the original GWAS. A meta-analysis of the GWAS and replication cohort 
(n=24,966 cases, 78,454 controls) yielded a highly significant P of 2.31x10-12 (OR=1.38, 
95%CI, 1.26-1.51)(Figure 2). These results support the association of KIF5A 
p.Pro986Leu with ALS. However, at this point we cannot definitely state that the 
missense variant is the primary risk factor, as we cannot rule out other variants in linkage 
disequilibrium.  
 
Additional Screening of LOF Variants in KIF5A 
We next performed mutational screening of KIF5A in an additional cohort of 9,046 ALS 
cases that had not been included in our original RVB analysis. This revealed two 
additional carriers of C-terminal variants, namely a carrier of an exon 26 frameshift 
mutation (p.Asn997fs) and a carrier of an exon 27 splice altering mutation (c.2993-
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1G>A, Table 3). Additionally, one patient was observed to carry a predicted splice 
altering variant proximal to exon 3 (c.291+5G>A). However, this variant was not 
supported as creating an aberrant transcript by ASSEDA. The frequency of LOF variants 
in this cohort (2/9,046 cases, 0.022%), which primarily comprised of sporadic ALS cases, 
is lower than that observed in our original FALS cohort (0.703%), suggesting that KIF5A 
LOF variants display a high penetrance. LOF variants were not observed in a follow up 
panel of 1,955 controls. 
 
ALS-Associated Mutations in KIF5A are Distinct from SPG10/CMT2 Mutations 
Missense mutations within KIF5A are a known cause of hereditary spastic paraparesis 
(spastic paraplegia type 10, autosomal dominan; OMIM #604187) and of Charcot-Marie-
Tooth disease Type 2 (CMT2)  
(Crimella et al., 2011; Jennings et al., 2017; Liu et al., 2014; Reid et al., 2002). Although 
SPG10 and CMT2 share clinical features with ALS, a careful examination of the clinical 
records of the ALS cases with LOF mutations in KIF5A ruled out misdiagnosis. 
Furthermore, we detected no variants previously associated with SPG10 or CMT2 in our 
FALS cohort (Liu et al., 2014).  
 
To further elucidate genotype-phenotype relationships, we evaluated the location of 
mutations within KIF5A. Interestingly, mutations contributing to SPG10 and to CMT2 
are found almost exclusively missense changes and located in the N-terminal motor 
domain (amino acids 9-327) of KIF5A (Figure 5). In contrast, the mutations identified as 
contributing to ALS are found predominantly in the C-terminal cargo binding region of 
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KIF5A (amino acids 907-1032) with the highly penetrant FALS mutations showing LOF. 
These results indicate that the functional domain mutated in KIF5A dictates the clinical 
phenotype, resulting in distinct yet overlapping neurodegenerative diseases.  
 
Patients with KIF5A LOF Mutations Display Younger Age at Onset and Longer 
Survival 
To establish the existence of any commonalities between patients with LOF mutations in 
the C-terminal region of KIF5A, we evaluated their clinical phenotype. Cases with LOF 
mutations exhibited a median age of onset at 46.5 years (n=19, Table S6). This is lower 
than the age of onset reported for ALS in epidemiological studies (65.2 years, 
interquartile range 56.0-72.2) (ALSGEN Consortium et al., 2013). Interestingly, we also 
observed an increased disease duration (survival) in patients harboring these LOF 
mutations. The median survival time of ALS patients is 20 – 36 months (ALSGEN 
Consortium et al., 2013). In contrast, cases with LOF mutations exhibited a median 
survival of nearly 10 years (117 months)(n=17, Table S6). Patients with uncomplicated 
types of hereditary spastic paraparesis and CMT2 display a normal life 
expectancy(Patzkó and Shy, 2011).  
 
DISCUSSION 
We previously identified KIF5A as a candidate gene for ALS in our previous study that 
lacked the power to draw a definitive conclusion (Kenna et al., 2016). KIF5A was also a 
candidate ALS gene in a previous GWAS, though it similarly failed to reach genome-
wide significance (McLaughlin et al., 2017; van Rheenen et al., 2016). Here, we have 
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confirmed KIF5A as an ALS-associated gene through two independent approaches. By 
performing a GWAS involving ~80,000 samples, we identified a missense variant within 
the KIF5A gene that reached genome-wide significance for association with ALS risk 
(P=6.4 x 10-10, OR= 1.38). In an independent line of investigation, we applied RVB to 
exome sequencing of ~21,000 samples and identified an exome-wide significant 
association between FALS risk and rare KIF5A LOF variants (OR=41.16, P=3.8 x 10-9). 
The GWAS and the exome gene burden signals were completely independent, as none of 
the cases carrying the p.Pro986Leu variant also carry LOF mutations. Follow up analyses 
of KIF5A in independent replication cohorts confirmed our initial finding and resulting in 
a highly significant association for both the p.Pro986Leu variant resulting (P=2.37 x 10-
12, OR=1.38) and revealed two additional carriers of LOF variants in 9,046 ALS cases. 
Taken together our results indicate that the p.Pro986Leu KIF5A variant may represent a 
relatively common, but low penetrance risk allele for ALS, while LOF variants constitute 
rare, but high penetrance risk factors. 
 
Kinesins are microtubule-based motor proteins involved in intracellular transport of 
organelles within eukaryotic cells. In mammals, there are three heavy chain isoforms of 
KIF5: KIF5A, KIF5B and KIF5C (Miki et al., 2001). The three proteins homo- and 
heterodimerize through their coiled-coiled stalk domain, and create a complex with two 
kinesin light chains via binding to the tail domain (Hirokawa et al., 1989). The complex 
of KIF5s and kinesin light chains is called Kinesin-1. All three KIF5 genes are expressed 
in neurons (Kanai et al., 2000) and function to transport many cargos by binding to 
distinct adaptor proteins.  
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The central role of kinesins in axonal transport lead us to speculate that mutations in 
KIF5A cause disease by disrupting axonal transport. Indeed, defects in axonal transport 
are a common observation in ALS patients and are already known to directly contribute 
to motor neuron degeneration pathogenesis (Chevalier-Larsen and Holzbaur, 2006; 
Hirokawa et al., 2010; Millecamps and Julien, 2013). KIF5 mediates the transport of 
granules containing both RNA and RNA binding proteins within neuronal dendrites and 
axons (Kanai et al., 2004). Among these cargos are the ALS-associated proteins FUS and 
hnRNPA1 (Kim et al., 2013; Kwiatkowski et al., 2009; Vance et al., 2009). Similarly, 
KIF5 mediates the transport of VAPB through the adaptor protein protrudin (Matsuzaki 
et al., 2011), and mutations in the VAPB gene have been identified in ALS and late-onset 
spinal muscular atrophy (Nishimura et al., 2005; 2004). KIF5 is responsible for the 
axonal transport of neurofilaments (Wang and Brown, 2010) and KIF5A knockout mice 
display abnormal transport of neurofilaments (Xia et al., 2003). Abnormal accumulation 
of neurofilaments are a pathological hallmark of ALS and rare mutations in 
neurofilament heavy polypeptide (NEFH) are associated with ALS (Al-Chalabi et al., 
1999). 
 
KIF5 also contributes to the transport of mitochondria (Kanai et al., 2000; Tanaka et al., 
1998) and motor neurons derived from KIF5A-/- mice display transport deficits and 
reduced survival (Karle et al., 2012). Impaired transport and dysfunction of mitochondria 
represent another common hallmark observed in ALS patients  
(Chevalier-Larsen and Holzbaur, 2006; Palomo and Manfredi, 2015; Smith et al., 2017). 
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KIF5 also contributes to the transport of AMPA-type (Heisler et al., 2014; Setou et al., 
2002) and GABA(A) receptors (Nakajima et al., 2012). In keeping with reported ALS 
genes such as NEK1 (Thiel et al., 2011) and PFN1 (Wu et al., 2012), modulation of 
KIF5A expression has been shown to influence the formation of neurite like membrane 
protrusions (Matsuzaki et al., 2011). Given its critical interactions with the cytoskeleton, 
the identification of KIF5A mutations further extends the list of cytoskeletal related 
proteins implicated in ALS pathogenesis, such as PFN1, TUBA4A, NEFH and peripherin 
(Al-Chalabi et al., 1999; Gros-Louis, 2004; Smith et al., 2014; Wu et al., 2012). 
 
An important question raised by the current study is why variation within the C-terminal 
domain is associated with ALS, while variation of the N-terminus is associated with 
hereditary spastic paraparesis and Charcot-Marie-Tooth, type 2. KIF5A can be 
structurally divided into three domains: of these, the N-terminal domain binds 
microtubules, and is responsible for ATP hydrolysis and the kinesin motor activity; the 
central coiled-coil or stalk domain mediates heavy chain dimerization, while the C-
terminal or tail domain interacts with cargo molecules. Notably, both the p.Pro986Leu 
and ALS-associated LOF variants are consistently localized within the C-terminal 
domain of KIF5A. Conversely, missense mutations previously associated with hereditary 
spastic paraparesis and Charcot-Marie-Tooth, type 2 have been found in the central or N-
terminal motor domain. Missense mutations within this latter domain affect microtubule 
binding and/or ATP hydrolysis, resulting in a defective KIF5A-mediated anterograde 
transport of cargo along dendrites and axons. This, in turn, leads to the axonal retrograde 
degeneration observed both in hereditary spastic paraparesis and Charcot-Marie-Tooth, 
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type 2, two length-dependent axonopathies (Ebbing et al., 2008). Conversely, the primary 
cellular lesion in ALS is believed to occur within motor neuron cell bodies, where 
cytoplasmic protein aggregates are consistently observed, and to propagate anterograde 
along neurites. Interestingly, LOF variants within the C-terminal domain of KIF5A are 
expected to disrupt binding with specific cargo proteins, possibly leading to their 
accumulation and seeding aggregation within the cell body and their deficiency at neurite 
terminals. Deficiency in KIF5A expression and cargo binding has been associated to 
accumulation of phosphorylated neurofilaments and amyloid precursor protein within 
neuronal cell bodies, and subsequent neurodegeneration, in patients with multiple 
sclerosis (Hares et al., 2016). While differences in KIF5A kinetics and KIF5A 
interactions constitute one possibility to explain the phenotypic heterogeneity, it is also 
possible that C-terminal and N-terminal variants act through a common mechanism but 
that a difference in the relative extent of loss or gain of function toxicities leads to milder 
(i.e. hereditary spastic paraplegia, Charcot-Marie-Tooth, type 2) or more severe (i.e. 
ALS) phenotypes. 
 
EXPERIMENTAL PROCEDURES 
 
Study cohorts 
GWAS cohort I. We undertook a GWAS of patients diagnosed with ALS (case cohort) 
and neurologically normal control individuals (control cohort). DNA was extracted from 
either whole blood or frozen brain tissue samples using standard procedures. All 12,663  
patients included in the case cohort had been diagnosed with ALS according to the El 
Escorial criteria (Brooks, 1994) by a neurologist specializing in ALS, had onset of 
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symptoms after age 18 years, and were of non-Hispanic white race/ethnicity. Both 
patients with familial ALS and patients with sporadic ALS were included in the analysis.  
 
For the control cohort, we used genotype data obtained from (a) the dbGaP web 
repository (www.ncbi.nlm.nih.gov/gap, n = 44,017 US samples) analysis; (b) the 
HYPERGENES Project (n = 887 Italian samples) (Salvi et al., 2012); and (c) the 
Wellcome Trust Case Control Consortium (www.wtccc.org.uk, n = 5,663 British 
samples). An additional 2,112 US and Italian control samples were genotyped in the 
Laboratory of Neurogenetics, National Institute on Aging. The control cohort was 
matched to the case cohort for race and ethnicity, but not for age or sex. A detailed 
description of the cohorts is available online in the Supplemental Information.  
 
Written consent was obtained from all individuals enrolled in this study, and the study 
was approved by the institutional review board approval of the National Institute on 
Aging (protocol number 03-AG-N329).  
 
GWAS cohort II. Summary statistics from a recently published GWAS based on logistic 
regression analysis involving 12,577 cases and 23,475 controls were downloaded from 
databrowser.projectmine.com. Additional details of the cohorts used in this study are 
available in van Rheenen et al (van Rheenen et al., 2016). 
 
FALS WXS discovery cohort. A total of 1,463 FALS patients were subjected to analysis 
by exome sequencing. Patients were recruited at specialist clinics in Australia (n=92), 
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Belgium (n=13), Canada (n=34), Germany (n=228), Ireland (n=18), Israel (n=26), Italy 
(n=230), Netherlands (n=50), Spain (n=60), Turkey (n=72), UK (n=223), USA (n=417). 
Familial history was considered positive for ALS if the proband had at least one affected 
relative within three degrees of relatedness.  
 
 
Control WXS discovery cohort. Read level exome sequencing data was obtained for a 
total of 41,410 non-ALS controls deposited in dbGAP and the EGA by various projects. 
Utilized dbGaP datasets include the Alzheimer's Disease Sequencing Project 
(ADSP) phs000572; University of Miami Udall Center of Excellence Identification of 
Rare Variants in PD through Whole Exome Sequencing phs000908; Myocardial 
Infarction Genetics Exome Sequencing Consortium: Ottawa Heart Study phs000806; 
Myocardial Infarction Genetics Exome Sequencing Consortium: Italian Atherosclerosis 
Thrombosis and Vascular Biology phs000814; Myocardial Infarction Genetics Exome 
Sequencing Consortium: Pakistan Risk Of Myocardial Infarction Study phs000917; 
Myocardial Infarction Genetics Exome Sequencing Consortium: U. of Leicester 
phs001000; Myocardial Infarction Genetics Exome Sequencing Consortium: Malmo Diet 
and Cancer Study phs001101; Yale Center for Mendelian Genomics (Y 
CMG) phs000744; Framingham Heart Study Allelic Spectrum Project phs000307; 
NHLBI GO-ESP Lung Cohorts Exome Sequencing Project: Genetic modifiers 
of Pseudomonas aeruginosa (Pa) lung infection acquisition in cystic fibrosis phs000254; 
National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component 
of the Exome Sequencing Project (FHS) phs000401; National Heart Lung and Blood 
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Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome Sequencing Project 
(JHS) phs000402; National Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart 
Cohorts Component of the Exome Sequencing Project (ARIC) phs000398; NHLBI GO-
ESP: Women's Health Initiative Exome Sequencing Project (WHI) - WHISP phs000281; 
NHLBI GO-ESP: Lung Cohorts Exome Sequencing Project (Pulmonary Arterial 
Hypertension) phs000290; NHLBI GO-ESP: Lung Cohorts Exome Sequencing Project 
(Lung Health Study of Chronic Obstructive Pulmonary Disease) phs000291; National 
Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the 
Exome Sequencing Project (CHS) phs000400; NHLBI GO-ESP: Lung Cohorts Exome 
Sequencing Project (COPDGene) phs000296; JHS Allelic Spectrum Project  phs000498; 
NHLBI GO-ESP Family Studies: Idiopathic Bronchiectasis of unknown etiology that is 
not related to cystic fibrosis or classic primary ciliary dyskinesia or immune deficiency or 
any other known causes phs000518; Genetic Epidemiology of COPD (COPDGene) 
Funded by the National Heart, Lung, and Blood Institute  phs000179; National Heart 
Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts Component of the Exome 
Sequencing Project (MESA) phs000403; NHLBI GO-ESP: Family Studies (Thoracic 
aortic aneurysms leading to acute aortic dissections) phs000347; NHLBI GO-ESP: Lung 
Cohorts Exome Sequencing Project (Asthma): Genetic variants affecting susceptibility 
and severity phs000422; NHLBI GO-ESP: Family Studies (Familial Atrial 
Fibrillation) phs000362; NHLBI GO-ESP Family Studies: Pulmonary Arterial 
Hypertension  phs000354; Building on GWAS: the U.S. CHARGE consortium - 
Sequencing (CHARGE-S): FHS phs000651; NHLBI GO-ESP: Family Studies 
(Hematological Cancers) phs000632; Building on GWAS for NHLBI-Diseases : the U.S. 
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CHARGE Consortium (CHARGE-S): ARIC phs000668; Building on GWAS for 
NHLBI-Diseases: The U.S. CHARGE Consortium (CHARGE-S): CHS phs000667. 
Utilized EGA projects included the UK10K COHORT ALSPAC EGAS00001000090; 
UK10K COHORT TWINSUK EGAS00001000108; UK10K NEURO ABERDEEN 
EGAS00001000109; UK10K NEURO ASD GALLAGHER EGAS00001000112; 
UK10K NEURO EDINBURGH EGAS00001000117; UK10K NEURO IOP COLLIER 
EGAS00001000121; UK10K_NEURO_MUIR EGAS00001000122; 
UK10K_RARE_HYPERCHOL EGAS00001000129; UK10K_RARE_SIR 
EGAS00001000130; UK10K_RARE_THYROID EGAS00001000131; 
UK10K_OBESITY_GS EGAS00001000242. 
 
ALS WXS/WGS replication cohort. Replication analyses included sequencing data for a 
further 9,046  ALS cases and 1,955 non-ALS controls that were not also represented in 
the FALS discovery set. These samples included 2,742 cases subjected to WXS as 
described previously (Cirulli et al., 2015); 719 cases subjected to WXS by the Laboratory 
of Neurogenetics, National Institute on Aging; 307 cases and 296 controls subjected to 
WGS by the Laboratory of Neurogenetics, National Institute on Aging; 161 cases 
subjected to WGS by the Create Consortium; 1,017 cases subjected to WGS by the 
Centre for genomics of neurodegenerative diseases; 4,100 cases and 1,659 controls 
subjected to WGS by the project MinE consortium.  
 
All samples included in the case cohort had been diagnosed with ALS according to the El 
Escorial criteria (Brooks, 1994) by a neurologist specializing in ALS.  
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We received approval for this study from the institutional review boards of the 
participating centers, and written informed consent was obtained from all patients 
(consent for research). 
 
Data generation and pre-processing 
Generation of SNP array callset. The case cohort (n = 12,663 samples) and part of the 
control cohort (n = 2,112) were genotyped in the Laboratory of Neurogenetics, National 
Institute on Aging, using HumanOmniExpress BeadChips (version 1.0, Illumina Inc., San 
Diego, CA) according to the manufacturer's protocol. These SNP genotyping arrays assay 
716,503 SNPs across the genome. Individual-level genotypes for these samples are 
available on the dbGaP web portal (www.ncbi.nlm.nih.gov/gap, accession number 
phs000101.v4.p1). The remainder of the control cohort had been previously genotyped on 
HumanOmni BeadChips (Illumina) as part of other GWAS efforts (see Table S2). 
Analyses were confined to the 595,692 autosomal SNPs that were common across the 
SNP genotyping arrays. 
 
Generation of FALS case-control  callset for exome-wide RVB discovery analysis. Exome 
sequencing of cases was performed as previously described (Kenna et al., 2016). Control 
exome sequences were generated as described under the relevant dbGAP and EGA 
project accessions. Sequence reads were aligned to human reference GRCh37 using 
BWA (Burrows-Wheeler Aligner) and processed according to recommended best 
practices (ref). Joint variant detection and genotyping of all samples were performed 
using the GATK HaplotypeCaller. Variant quality control was performed using the 
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GATK variant quality score recalibration method with default filters. A minimum variant 
quality by depth (QD) score of 2 was also imposed and all genotypes associated with 
genotype quality (GQ)< 20 were reset to missing. Variants were also excluded in the 
event of case or control call rates <70% (post genotype QC). All identified LOF variants 
were validated by Sanger sequencing. 
 
Generation of ALS case-control callset for KIF5A replication analysis. Data for the 
KIF5A locus was extracted from all independently generated sequencing datasets and 
remapped to GRCh37. Variant calling was performed using the GATK haplotype caller 
as described above. In addition to the KIF5A locus, data was also extracted for a panel of 
240,715 common variant sites and used to perform a single unified sample QC as 
described below. All identified LOF variants were validated by Sanger sequencing. 
 
Functional annotation of variants identified by WXS/WGS  
Variant calls were assigned predicted functional consequences using snpEFF (Single 
Nucleotide Polymorphism Effect) and dbscSNV (database of splice site consequences of 
Single Nucleotide Variants). Variants were classified as "loss of function" (LOF) where 
the sequence change was predicted to encode a premature stop codon, a frameshift 
causing insertion-deletion, a splice site disrupting SNV. Variants were classified as 
potentially splice altering if assigned an "ada" or "rf" score >0.7 by dbscSNV. Splice 
variants of potential interest were further assessed for putative effects on exon skipping 
using a secondary algorithm - automated splice site and exon definition server 
(ASSEDA)(Mucaki et al., 2013). 
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Statistical analyses.  
Analysis of SNP array genotypes. Standard quality-control procedures were applied to 
our genotype data using PLINK software package (version 1.9, PMID: 25722852). We 
excluded samples that demonstrated: call rates of less than 97.5%; non-European 
ancestry; abnormal F inbreeding coefficient; mismatch between phenotypic and 
genotypic gender; or, cryptic relatedness defined as identity-by-descent proportion of 
inheritance (pi_hat from PLINK) greater than 0.125. Samples in common between our 
study and van Rheenen's study were identified using the checksum program 
(id_geno_checksum.v2), and were removed from our analyses. We excluded palindromic 
SNPs, as well as SNPs with: call rates less than 95% in the US and Italian cohorts or less 
than 99% in the UK, French and Belgium cohorts; minor allele frequency less than 0.05 
in the control cohorts; Hardy-Weinberg equilibrium P less than 10-7 in the US and Italian 
control cohorts and less than 10-5 in the UK, French and Belgium cohorts; missingness by 
case-control status P less than 10-5; or SNPs associated between the UK and French 
control cohorts with P less than 5.0x10-8. After quality control, 8,229 case and 36,329 
control samples were included in the analysis, and 436,746 SNPs were available for 
imputation in the USA and Italy cohorts, and 420,131 SNPs were available in the UK, 
French and Belgium cohorts.  
 
Estimation of the haplotypes was performed with SHAPEIT (version 2.r790, PMID: 
23269371). Imputation was performed for individual batches based on ethnicity using the 
1000 Genomes Project dataset (phase 3, version 5a, release 2013-05-02, 
 22 
1000genomes.org) as reference and using Minimac3 software (version 1.0.11, PMID: 
27571263) with default settings. After imputation, principal components were calculated 
using PLINK software after removing known hypervariable regions and the 1 MB 
surrounding the C9orf72 region. After analysis of the Scree plots, 2 to 4 principal 
components were retained per cohort as covariates in the association analyses to 
compensate for any residual population stratification.  
 
Logistic regression was performed per batch using mach2dat software (version 1.0.24, 
PMID: 20517342) incorporating 2 to 4 principal components, age and gender as 
covariates, with dosage of imputed SNPs selected based on a Minimac3 R2 value of 
imputation accuracy greater than 0.3. SNPs with an absolute beta coefficient value above 
5 or with a minor allele frequency less than 0.01 were excluded from meta-analysis. 
Meta-analysis was then performed combining the association results of the 13 batches of 
our individual-level studies with van Rheenen's study summary statistics using METAL 
software (version 2011-03-25, PMID:20616382) under an inverse-weighted, fixed effect 
model. A threshold P of 5.0×10-8 was set for genome-wide significance after Bonferroni 
correction for multiple testing (Pe'er et al., 2008). 
 
The programming code used to analyze these data is freely available on GitHub (link to 
be supplied at publication), and GWAS summary statistics results for all tested SNPs are 
available from (link to be supplied at publication). 
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Analysis of WXS/WGS genotypes. For both the discovery and replication phases, samples 
were excluded from the study in the event of failing to meet standard genotype call rate, 
heterozygosity, duplication, relatedness or population stratification filters as summarized 
in Table S5 and as previously described (Kenna et al., 2016). Each of these filters was 
performed using a set of autosomal markers meeting all of the following criteria: call 
rate>0.95, MAF>0.01, p>0.001 for deviation from Hardy Weinberg equilibrium, LD 
pruning (R2<0.5, window size=50, step=5). Filtering of autosomal markers, sample call 
rate assessments and sample heterozygosity assessments were performed using PLINK 
v1.09. Study duplicates and sample relatedness within the WXS/WGS cohorts was 
identified using KING. Study duplicates between WXS/WGS cohorts and GWAS 
datasets were identified using the checksum program (id_geno_checksum.v2, 
https://personal.broadinstitute.org/sripke/share_links/checksums_download/).  Principal 
components analyses were performed using GCTA (Genome-wide Complex Trait 
Analysis).  
 
RVB analyses were performed by penalized logistic regression of case-control status with 
respect to number of minor alleles observed per sample per gene as described previously 
(Kenna et al., 2016). Analyses were only performed where the dataset contained >3 
variant allele occurrences. Replication analyses of rs113247976 were performed using 
the same logistic regression protocol as used for RVB analyses. All analyses were 
conditioned on the first 4 eigenvectors generated by principal components analysis of 
common variant profiles. Genomic inflation factors were calculated using genome-wide 
association analysis for quantitative, binary and time-till-event traits (GenABEL). 
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Candidate associations were tested for signs of call-rate or subcohort biases as outlined in 
Figures S6, S7. Meta-analysis of rs113247976 association results between sequencing 
and GWAS was performed using METAL. Unless otherwise indicated all statistical 
analyses were performed using R v3.2.0. 
 
RT-PCR analysis  
Total RNA was prepared from lymphoblast lines using Trizol reagent. Reverse 
transcription using Applied Biosystems RNA to cDNA kit (# 4368814) was performed 
with 0.5 ug with RNAse inhibitor in a 20 ul reaction using manufacturer's methods. PCR 
was carried out using NEB One Taq Hot Start DNA Polymerase (# M0481S), 2 ul RT 
reaction (representing 50 ng input RNA) and forward and reverse primer (0.15 uM each) 
in a 20 ul reaction. Amplification conditions were as follows: 94°C 30 sec, {94°C 20 sec, 
58°C 20 sec, 68°C 1 min} x 35, 68°C 5 min, 4°C hold. Amplification of both normal and 
mutant splice forms used primers F1 (CAGTGGAGCCACATCTTCTG) and R1 
(TCTCTTGGTGGAGAGGGAAA). Primers used for the specific amplification of the 
mutant splice form were F2 (CCAACATGGACAATGGAGTGA), which spans exons 26 
and 28, and R1.  
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Figure 1. Identification of association between KIF5A locus and ALS risk through 
GWAS. (A) Manhattan plot showing p-values from the discovery set GWAS. Analysis of 
a combined set of 20,806 cases and 59,804 controls is shown. The dashed red line 
denotes the threshold for genome-wide significance after multiple test correction (P < 
5.0x10-8). Five previously reported ALS associated genes are labeled in grey and one 
novel gene, KIF5A, is labeled in black. (B) Regional association plot of the KIF5A locus. 
Recombination rates are from HapMap phase 2 European ancestry samples. The R2 
pattern is based on most significant SNP per locus using 85 European ancestry samples 
(CEU) from the November 2010 release of the 1000 genomes project dataset. R2 of the 
p.Pro986Leu (rs113247976) with additional SNPs achieving genome-wide significance 
was 0.544 (rs117027576), 0.544 (rs118082508), 0.741 (rs116900480), and 0.347 
(rs142321490).  
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Figure 2. Discovery and replication for the association of the KIF5A p.Pro986Leu 
(rs113247976) variant with ALS. Analysis of the p.Pro986Leu (rs113247976) variant 
within each of the cohorts described is presented. Allelic association for all subcohorts 
were analyzed by logistic regression followed by a fixed-effects meta-analysis. The forest 
plot (right) displays the distribution of OR estimates across study cohorts with vertical 
dotted line denoting OR estimated under the meta-analysis.  
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Figure 3. Identification of association between KIF5A and ALS risk through rare 
variant burden analysis of exome sequencing. Manhattan plot showing gene-level p-
values from an exome-wide rare variant burden analysis. Analyses of 1,138 index FALS 
cases vs. 19,494 controls were restricted to rare LOF variants as previously defined 
(splice altering/nonsense, MAF<0.001)(Kenna et al., 2016). A minimum of 3 LOF gene 
variants were required for analysis. The dashed red line denotes the threshold for exome-
wide significance after correction for 11,472 genes (4.36 x 10-6). Previously reported 
(grey) and novel (black) genes exhibiting a significant excess of rare LOF variants in 
patients are shown. 
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Figure 4. ALS associated loss of function variants of KIF5A disrupt C-terminal 
sequence by inducing skipping of exon 27. (A) Single nucleotide variants (SNVs) 
within KIF5A identified in ALS patients are clustered at the 5’ and 3’ splice junctions of 
exon 27. The consensus splice sequence is shown. (B) ALS associated SNVs are 
predicted to induce skipping of exon 27 and result in an aberrant mRNA transcript. (C) 
The skipping of exon 27 of KIF5A yields an out-of-frame and extended disrupted C-
terminal peptide sequence. The amino acids in red signify the divergence from the normal 
protein. (D) RT-PCR was performed using RNA from lymphoblasts derived from ALS 
patients without (Control) or with (ALS) the loss of function c.3020+2T>A allele 
predicted to induce skipping of exon 27. PCR reactions used primers to either amplify 
both normal (155 bp) and mutant (127 bp) splice forms (left panel) or specifically the 
mutant splice form (80 bp)(right). The arrow represents the position of the mutant 
specific product in the left panel. 
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Figure 5. KIF5A ALS mutations show distinct localization to missense mutations 
previously associated with SPG10 and CMT2. Causative mutations for SPG10 and 
CMT2 described within the literature (Crimella et al., 2011; Jennings et al., 2017; Liu et 
al., 2014; Reid et al., 2002) and ALS associated mutation identified within this study are 
shown. As illustrated, mutations causative for SPG10/CMT2 are predominantly missense 
changes and located in the N-terminal motor domain. In contrast, ALS mutations are 
primarily located at the C-terminal motor domain with most penetrant displaying LOF.   
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SNP Information  
Present Study 
(8,229 Cases / 36,329 Controls) 
 
Van Rheenen et al. 
(12,577 Cases / 23,475 Controls) 
 
Combined Discovery Set 
(20,806 Cases / 59,804 Controls) 
SNP Chr Position Gene  
Case 
MAF 
Control 
MAF 
OR 
[95% CI] 
P  
Case 
MAF 
Control 
MAF 
OR 
[95% CI] 
P  
Case 
MAF 
Control 
MAF 
OR 
[95% CI] 
P 
Novel Loci                
rs117027576 12 57,316,603 KIF5A  1.55% 1.27% 
1.45  
[1.20-1.76] 
1.1x10-4  1.98% 1.59% 
1.33 
[1.16-1.53] 
4.3x10-5  1.81% 1.40% 
1.37 
[1.23-1.54] 
2.3x10-8 
rs118082508 12 57,318,819 KIF5A  1.56% 1.28% 
1.45  
[1.20-1.76] 
1.0x10-4  1.98% 1.60% 
1.33 
[1.16-1.53] 
3.8x10-5  1.81% 1.41% 
1.37 
[1.23-1.54] 
2.0x10-8 
rs113247976* 12 57,975,700 KIF5A  1.83% 1.42% 
1.46  
[1.23-1.74] 
9.2x10-6  2.14% 1.70% 
1.33 
[1.17-1.52] 
1.1x10-5  2.02% 1.53% 
1.38 
[1.24-1.53] 
6.4x10-10 
rs116900480 12 58,656,105 KIF5A  1.75% 1.46% 
1.42  
[1.21-1.68] 
1.9x10-5  2.08% 1.66% 
1.34 
[1.18-1.53] 
7.1x10-6  1.95% 1.54% 
1.37 
[1.24-1.52] 
6.6x10-10 
rs142321490 12 58,676,132 KIF5A  1.79% 1.48% 
1.43  
[1.21-1.68] 
1.5x10-5  2.08% 1.66% 
1.34 
[1.18-1.53] 
8.0x10-6  1.97% 1.55% 
1.37 
[1.24-1.52] 
6.1x10-10 
Previously Published Loci                
rs10463311 5 150,410,835 TNIP1  73.19% 74.84% 
0.94 
[0.89-0.98] 
7.8x10-3  73.34% 75.79% 
0.91 
[0.87-0.94] 
8.5x10-7  73.28% 75.21% 
0.92 
[0.89-0.95] 
4.0x10-8 
rs3849943 9 27,543,382 C9orf72  71.79% 76.31% 
0.84 
[0.80-0.88] 
1.4x10-12  72.78% 76.5% 
0.83 
[0.80-0.87] 
4.0x10-19  72.39% 76.38% 
0.84 
[0.81-0.86] 
3.8x10-30 
rs74654358 12 64,881,967 TBK1  3.77% 4.01% 
1.20 
[1.07-1.34] 
1.6x10-3  5.12% 4.61% 
1.23 
[1.13-1.34] 
7.7x10-7  4.59% 4.25% 
1.22 
[1.14-1.30] 
4.7x10-9 
rs12973192 19 17,753,239 UNC13A  67.62% 69.37% 
0.86 
[0.82-0.91] 
1.3x10-8  64.52% 66.00% 
0.9 
[0.87-0.93] 
2.4x10-8  65.75% 68.05% 
0.89 
[0.86-0.91] 
3.9x10-15 
rs75087725 21 45,753,117 C21orf2  0.70% 0.46% 
1.99 
[1.44-2.75] 
2.2x10-5  1.83% 1.27% 
1.61 
[1.39-1.87] 
8.7x10-11  1.38% 0.78% 
1.67 
[1.46-1.91] 
1.8x10-14 
 
Table 1. SNPs achieving genome-wide significance in the discovery GWAS. Position is based on Human Genome Assembly build 37. Nearest gene or 
previously published gene names are included. Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; 95% CI, confidence interval; *, rs113247976 
represents the p.Pro986Leu variant in KIF5A (NM_004984.2). 
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Gene FALS Control OR P 
KIF5A 6 (0.53%) 3 (0.02%) 32.07 (9.05-135.27) 5.55x10-7 
TBK1 8 (0.70%) 9 (0.05%) 15.11 (5.81-38.69) 5.58x10-7 
NEK1 12 (1.05%) 32 (0.16%) 6.64 (3.32-12.51) 1.68x10-6 
CALHM2 7 (0.62%) 9 (0.05%) 12.13 (4.47-31.79) 9.19x10-6 
COL14A1 8 (0.70%) 16 (0.08%) 8.04 (3.32-18.08) 2.72x10-5 
AK1 10 (0.88%) 34 (0.17%) 5.37 (2.55-10.41) 5.62x10-5 
ATRN 5 (0.44%) 9 (0.05%) 11.06 (3.57-31.02) 1.66x10-4 
VLDLR 5 (0.44%) 9 (0.05%) 10.87 (3.51-30.43) 1.79x10-4 
FUS 4 (0.35%) 4 (0.02%) 16.53 (4.25-64.33) 2.08x10-4 
ZMYND12 6 (0.53%) 12 (0.06%) 7.92 (2.86-19.96) 2.61x10-4 
 
Table 2. Top ALS associations identified through RVB of FALS and control exome sequencing results. 
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Position Variant Exon cDNA Description 
Predicted Exon 
Skipping Gender 
Age of Onset 
(years) 
Site of 
Onset 
Survival 
(months) 
Alive 
(yes/no) 
 
Control Variants          
57,963,470 A>G 11 c.1117+4A>G 3' Splice Junction P M n/a n/a n/a n/a 
57,966,423 C>T 15 c.1630C>T p.Arg544* - F n/a n/a n/a n/a 
57,976,884 G>C 28 c.3021G>C 5' Splice Junction N F n/a n/a n/a n/a 
 
FALS Variants 
         
  
57,975,729 GA>A 26 c.2987delA p.Asp996fs - M 45 n/a n/a n/a 
57,976,382 C>T 27 c.2993-3C>T 5' Splice Junction  Y M 29 L >264 Y 
57,976,385 GA>G 27 c.2996delA p.Asn999fs - M 42 L >12 Y 
57,976,411 A>G 27 c.3019A>G p.Arg1007Gly Y F 53 L 45 N 
57,976,412 G>A 27 c.3020G>A p.Arg1007Lys Y M 50 L >108 Y 
57,976,413 G>A 27 c.3020+1G>A 3' Splice Junction  Y M 45 B >220 Y 
57,976,414 T>A 27 c.3020+2T>A 3' Splice Junction  Y M 46 B 124 N 
57,976,415 A>G 27 c.3020+3A>G 3' Splice Junction  Y M 50 B 54 N 
          
  
SALS Variants 
      
  
57,957,481 G>A 3 c.291+5G>A 3' Splice Junction N n/a n/a n/a n/a n/a  
57,975,731 CA>C 26 c.2989delA p.Asn997fs - F 50 L >96 Y 
57,976,384 G>A 27 c.2993-1G>A 5' Splice Junction  Y n/a  52 B n/a   n/a 
 
Table 3. Loss of function variants within KIF5A identified in probands. P, possible; Y, yes; N, no; M, male; F, female; L, limb onset; B, bulbar onset, 
n/a, not available or applicable. Note, ASSEDA does not predict exon skipping based on frameshifts or non-sense mutations (Mucaki et al., 2013).  
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Figure S1. Multi-dimensional scaling plot of the 44,558 genotyped samples included in 
analysis compared to the HapMap populations. 
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Figure S2. QQ plot of P-values from the meta-analysis based on logistic regression 
analysis. The black curve represents all SNPs, and the red curve represent SNPs after 
excluding variants within +/- 200 kilobases of C9orf72 and UNC13a loci. Raw lambda = 
1.042 and adjusted lambda scaled to 1,000 cases and 1,000 controls = 1.001 based on the 
entire SNP dataset. 
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Figure S3. Power to detect associate loci for a cohort of 20,806 cases and 59,804 control 
subjects. Power calculations were performed using the QUANTO software program 
(version 1.2.4, available from: http://hydra.usc.edu/gxe) under an additive model 
assuming two-tailed P value of 5.0x10-8 (threshold P value for significance after 
Bonferroni correction for multiple testing), population risk of 0.0001 and complete 
linkage equilibrium between the genotyped SNP and the causative allele. Based on our 
findings for rs142321490 in the KIF5A locus on chromosome 12 (see Table 1 in the 
main paper), a cohort of 20,806 cases and 59,804 controls has ~99.5% power to detect an 
associated SNP with a minor allele frequency of 0.018 and an odds ratio of 1.37 under the 
additive model.  
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Figure S4. Principle components analysis of samples included in RVB analysis compared 
to the Human Diversity Panel. Ancestry filtering of FALS discovery cohort. LASER was 
used to generate PCA coordinates for samples from the Human genome diversity panel 
(HGDP). Samples from the FALS discovery cohort were then mapped to this reference 
co-ordinate space. The discovery cohort was restricted to cases and controls occurring 
within 3SD of mean for European HGDP samples along principle components 1-4.   
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Figure S5. QQ plot of P-values from the gene-based rare variant burden analysis of 
exome data. The black curve represents all genes. The calculated genomic inflation factor 
(λ = 0.93) was calculated on the entire gene dataset. 
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Figure S6. Control-control Analyses. P-values from RVB analysis of FALS cases vs 
controls (y-axis) are plotted against minimum p-values from RVB analyses of candidate 
batch effects (x-axis). To assess the potential impact of batch effects, the sample cohort 
was divided into 28 pseudo case-control groups based on the sequencing center or 
associated dbGAP project. Loci showing possible association with non-ALS related batch 
effects are coloured light grey. No evidence of confounder bias was observed for KIF5A 
or previously reported ALS genes. 
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Figure S7. Plot of variant call rate across the KIF5A protein-coding region in FALS 
versus controls analyzed by RVB. 
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Figure S8. Principle Components analysis of samples included in KIF5A replication 
cohort. 
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Table S1. Demographics and baseline characteristics of patients diagnosed with ALS and control individuals included in analysis 
 
 US 
 
Italian 
 
UK 
 French &  
Belgian 
 
Total cohort 
 
cases controls  cases controls  cases controls  cases controls  cases controls 
Sample 
number 
3,777 33,365 
 
2,853 2,143 
 
449 226 
 
1,150 595 
 
8,229 36,329 
               
Female 
(%) 
1,515 
(40.1) 
23,870 
(71.5) 
 1,239 
(43.4) 
896 
(41.8) 
 193 
(43.0) 
109 
(48.2) 
 486 
(42.3) 
422 
(70.9) 
 3,433 
(41.7) 
25,297 
(69.6) 
               
Age 
(SD) 
58.1 
(12.3) 
64.2 
(13.3) 
 61.8 
(11.8) 
50.6 
(17.4) 
 60.3 
(12.8) 
57.0 
(0.0) 
 60.5 
(12.6) 
66.9 
(16.8) 
 59.8 
(12.3) 
63.4 
(13.9) 
               
Bulbar-onset* 
(%) 
963 
(25.5) 
- 
 741 
(26.0) 
- 
 141 
(31.4) 
- 
 357 
(31) 
- 
 2,202 
(26.8) 
- 
               
Family 
history† 
(%) 
458 
(12.1) 
- 
 
248  
(8.7) 
- 
 
54 
(12.0) 
- 
 
195 
(17.0) 
- 
 
955 
(11.6) 
- 
SD, standard deviation. *Data not available for site of symptom onset for 199 patients. †Data not available for familial history of 154 
patients.
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Table S2. DbGaP studies contributing to GWAS.  
 
Accession 
Number 
Study 
Sample 
number 
Females 
(%) 
Average 
age (SD) 
Genotyping 
platform 
Ascertainment 
criteria 
phs000001 
NEI Age-Related Eye Disease Study 
(AREDS) 
1,644 959 (58.3) 68.2 (4.8) HumanOmni2.5 Population controls 
phs000007 Framingham Cohort 1,298 718 (55.3) 75.7 (8.6) HumanOmni5 Population controls 
phs000187 
High Density SNP Association Analysis 
of Melanoma 
1,027 414 (40.3) 51.3 (12.6) HumanOmniExpress Population controls 
phs000196 
CIDR: The NeuroGenetics Research 
Consortium Parkinson's Disease Study 
10 6 (60) 74.3 (18.6) HumanOmni1 Population controls 
phs000292 
GENEVA Genetics of Early Onset Stroke 
(GEOS) Study 
89 0 (0) 41.5 (6.4) HumanOmni1 Population controls 
phs000304 Genes and Blood Clotting Study (GABC) 403 259 (64.3) 21.6 (3.3) HumanOmni1 Population controls 
phs000315 
Woman's Health Initiative (WHI 
GARNET) 
4,206 4206 (100) 65.7 (6.9) HumanOmni1 Population controls 
phs000368 
Polycystic Ovary Syndrome Genetics 
(POLYGEN) 
2,974 2973 (100) 46.8 (15.2) HumanOmniExpress Population controls 
phs000372 
Alzheimer's Disease Genetics Consortium 
Genome Wide Association Study 
533 335 (62.9) 75.8 (9) HumanOmniExpress Population controls 
phs000394 
Autopsy-Confirmed Parkinson Disease 
GWAS Consortium (APDGC) 
299 152 (50.8) 82.1 (12.6) HumanOmni1 Population controls 
phs000397 NIA Long Life Family Study (LLFS) 1,804 957 (53) 65.9 (12.3) HumanOmni2.5 Population controls 
phs000404 
The Genetic Architecture of Smoking and 
Smoking Cessation 
81 50 (61.7) 36.6 (5.9) HumanOmni2.5 Population controls 
phs000421 
A Genome-Wide Association Study of 
Fuchs' Endothelial Corneal Dystrophy 
497 294 (59.2) 70.4 (10.2) HumanOmni2.5 Population controls 
phs000428 Health and Retirement Study (HRS) 9,394 5437 (57.9) 68.4 (9.4) HumanOmni2.5 Population controls 
phs000615 NINDS Stroke Genetics Network (SiGN) 743 416 (56) 56 (16.1) HumanOmni5 Population controls 
phs000675 
GWAS on Selected WHI Hormone Trial 
European Americans 
5,626 5626 (100) 68 (5.9) HumanOmni1 Population controls 
phs000801 NCI Non-Hodgkin Lymphoma GWAS 1,544 790 (51.2) 58.4 (11.6) HumanOmniExpress Population controls 
phs000869 
Barrett's and Esophageal Adenocarcinoma 
Genetic Susceptibility Study (BEAGESS) 
1,174 271 (23.1) 61.3 (10.9) HumanOmni1 Population controls 
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Table S3. SNPs achieving genome-wide significance based on logistic regression  
 
 
SNP Information 
 Present Study 
(8,229 Cases / 36,329 Controls) 
 Van Rheenen et al. 
(12,577 Cases / 23,475 Controls) 
 Combined Discovery Set 
(20,806 Cases / 59,804 Controls) 
SNP Chr Position Gene 
 Beta 
[SE] 
OR 
[95% CI] 
P 
 Beta 
[SE] 
OR 
[95% CI] 
P 
 
I2 
Beta 
[SE] 
OR 
[95% CI] 
P 
Novel Loci              
rs117027576 12 57,316,603 KIF5A 
 0.373 
[0.096] 
1.45  
[1.20-1.76] 
1.1x10-4 
 0.286 
[0.070] 
1.33 
[1.16-1.53] 
4.3x10-5 
 
25.6 
0.316 
[0.057] 
1.37 
[1.23-1.54] 
2.3x10-8 
rs118082508 12 57,318,819 KIF5A 
 0.374 
[0.096] 
1.45  
[1.20-1.76] 
1.0x10-4 
 0.288 
[0.070] 
1.33 
[1.16-1.53] 
3.8x10-5 
 
25.8 
0.317 
[0.051] 
1.37 
[1.23-1.54] 
2.0x10-8 
rs113247976* 12 57,975,700 KIF5A 
 0.381 
[0.086] 
1.46  
[1.23-1.74] 
9.2x10-6 
 0.288 
[0.066] 
1.33 
[1.17-1.52] 
1.1x10-5 
 
0.0 
0.322 
[0.052] 
1.38 
[1.24-1.53] 
6.4x10-10 
rs116900480 12 58,656,105 KIF5A 
 0.354 
[0.083] 
1.42  
[1.21-1.68] 
1.9x10-5 
 0.294 
[0.065] 
1.34 
[1.18-1.53] 
7.1x10-6 
 
0.0 
0.317 
[0.051] 
1.37 
[1.24-1.52] 
6.6x10-10 
rs142321490 12 58,676,132 KIF5A 
 0.357 
[0.082] 
1.43  
[1.21-1.68] 
1.5x10-5 
 0.292 
[0.066] 
1.34 
[1.18-1.53] 
8.0x10-6 
 
0.0 
0.317 
[0.056] 
1.37 
[1.24-1.52] 
6.1x10-10 
Previously Published Loci              
rs10463311 5 150,410,835 TNIP1 
 -0.065 
[0.024] 
0.94 
[0.89-0.98] 
7.8x10-3 
 -0.100 
[0.020] 
0.91 
[0.87-0.94] 
8.5x10-7 
 
0.0 
-0.085 
[0.016] 
0.92 
[0.89-0.95] 
4.0x10-8 
rs3849943 9 27,543,382 C9orf72 
 -0.17 
[0.024] 
0.84 
[0.80-0.88] 
1.4x10-12 
 -0.181 
[0.020] 
0.83 
[0.80-0.87] 
4.0x10-19 
 
0.0 
-0.176 
[0.016] 
0.84 
[0.81-0.86] 
3.8x10-30 
rs74654358 12 64,881,967 TBK1 
 0.182 
[0.058] 
1.20 
[1.07-1.34] 
1.6x10-3 
 0.206 
[0.042] 
1.23 
[1.13-1.34] 
7.7x10-7 
 
0.0 
0.198 
[0.034] 
1.22 
[1.14-1.30] 
4.7x10-9 
rs12973192 19 17,753,239 UNC13A 
 -0.149 
[0.026] 
0.86 
[0.82-0.91] 
1.3x10-8 
 -0.106 
[0.019] 
0.9 
[0.87-0.93] 
2.4x10-8 
 
38.6 
-0.121 
[0.015] 
0.89 
[0.86-0.91] 
3.9x10-15 
rs75087725 21 45,753,117 C21orf2 
 0.687 
[0.162] 
1.99 
[1.44-2.75] 
2.2x10-5 
 0.479 
[0.074] 
1.61 
[1.39-1.87] 
8.7x10-11 
 
31.1 
0.515 
[0.067] 
1.67 
[1.46-1.91] 
1.8x10-14 
 
Position is based on Human Genome Assembly build 37. Nearest gene or previously published gene names are included. Chr, chromosome; SE, standard error; 
OR, odds ratio; 95% CI, 95% confidence interval; *, rs113247976 represents the p.Pro986Leu variant in KIF5A (NM_004984.2). 
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Table S4.  Suggestive SNPs with P-value less than 5.0x10-7 in genome-wide association analyses 
 
 
SNP Information  
Present Study 
(8,229 Cases / 36,329 Controls) 
 
Van Rheenen et al. 
(12,577 Cases / 23,475 Controls) 
 
Combined Discovery Set 
(20,806 Cases / 59,804 Controls) 
SNP Chr Position Gene  
Case 
MAF 
Control 
MAF 
OR 
[95% CI] 
P  
Case 
MAF 
Control 
MAF 
OR 
[95% CI] 
P  
Case 
MAF 
Control 
MAF 
OR 
[95% CI] 
P 
rs17070492 8 2,420,855 LOC101927815  10.01% 9.76% 
1.03 
[0.97-1.09] 
3.4x10-1  9.17% 10.09% 
1.16 
[1.09-1.23] 
1.3x10-6  9.50% 9.89% 
1.13 
[1.08-1.19] 
1.0 x10-7 
rs10139154 14 31,147,498 SCFD1  34.10% 31.30% 
1.13 
[1.09-1.18] 
4.1x10-12  33.76% 31.17% 
1.08 
[1.04-1.12] 
1.9x10-5  33.90% 31.25% 
1.08 
[1.05-1.11] 
1.4 x10-7 
rs10143310 14 92,540,381 ATXN3  24.85% 24.36% 
1.03 
[0.99-1.07] 
1.9x10-1  24.04% 22.95% 
1.08 
[1.04-1.13] 
2.6x10-4  24.36% 23.81% 
1.09 
[1.05-1.12] 
3.2 x10-7 
rs9901522 17 14,673,934 PMP22  7.08% 6.31% 
1.13 
[1.06-1.21] 
2.5x10-4  6.87% 5.97% 
1.16 
[1.08-1.24] 
4.6x10-5  6.95% 6.18% 
1.16 
[1.10-1.22] 
8.6 x10-8 
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Table S5. Quality control filtering of the FALS Discovery and KIF5A replication Cohorts.  
 
 
FALS discovery  
Cohort Cases Controls 
Initial Sample Set 1,463 41,410 
Post HGDP Continental Ancestry Filter 1,397 24,563 
Post Call Rate Filter 1,331 20,789 
Post Heterozygosity Filter 1,319 20,664 
Post Relatedness Filter 1,138 19,494 
 
 
rs113247976 replication 
Cohort Cases Controls 
Initial Sample Set 12,415 21,533 
Post Call Rate Filter 11,916 21,050 
Post Heterozygosity Filter 11,721 21,028 
Post Ancestry Filter (PCA) 11,373 21,009 
Post Relatedness & GWAS Checksum Filter 4,160 18,650 
 
 
LOF screen 
Cohort Cases Controls 
Initial Sample Set 12,415 21,533 
Post Call Rate Filter 11,916 21,050 
Post Heterozygosity Filter 11,721 21,028 
Post Ancestry Filter (PCA) 11,373 21,009 
Post Relatedness & FALS Discovery Overlap Filter 9,046 1,955 
 
See Materials and Methods for details on filtering parameters.  
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Table S6. Clinical information of probands and relatives carrying KIF5A LOF Variants. 
 
Position Variant Relation to 
Proband 
DNA 
Available 
Exon cDNA Description Gender Age of Onset 
(years) 
Site of 
Onset 
Survival 
(months) 
Alive 
57,975,729 GA>A Proband Y 26 c.2987delA p.Asp996fs M 45 n/a n/a n/a 
57,976,382 C>T Proband Y 27 c.2993-3C>T 5' Splice Junction M 29 L >264 Y 
57,976,382 C>T Sister Y 27 c.2993-3C>T 5' Splice Junction F 52 L 84 N 
57,976,382 C>T Brother Y 27 c.2993-3C>T 5' Splice Junction M 18 L 324 N 
  Brother N    M n/a L n/a N 
57,975,731 CA>C Sporadic Y 26 c.2989delA p.Asn997fs F 50 L >96 Y 
57,976,384 G>A Sporadic N 27 c.2993-1G>A 5' Splice Junction n/a 52 B n/a n/a 
57,976,385 GA>G Proband Y 27 c.2996delA p.Asn999fs M 42 L >12 Y 
  Brother N    M 38 n/a 24 N 
57,976,411 A>G Proband Y 27 c.3019A>G p.Arg1007Gly F 53 L 45 N 
57,976,412 G>A Proband Y 27 c.3020G>A p.Arg1007Lys M 50 L >108 Y 
57,976,413 G>A Proband Y 27 c.3020+1G>A 3' Splice Junction M 45 B >220 Y 
  Parent N    n/a 47 n/a 156 N 
  Uncle/Aunt N    n/a 57 n/a 144 N 
  Uncle/Aunt N    n/a 55 n/a 121 N 
  Uncle/Aunt N    n/a 46 n/a 24 N 
57,976,414 T>A Proband Y 27 c.3020+2T>A 3' Splice Junction M 46 B 124 N 
57,976,414 T>A Brother Y 27 c.3020+2T>A 3' Splice Junction M 48 L 117 N 
  Mother N    F 35 L 144 N 
57,976,415 A>G Proband Y 27 c.3020+3A>G 3' Splice Junction M 50 B 54 N 
 
All mutations were heterozygous; Genomic coordinates in NCBI build 37; Protein change based on transcript NM_004984.3;  
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Supplementary Table 7.  
 
Analysis FALS Control OR (95% CI) P 
Missense - Full CDS 9 (0.79%) 80 (0.41%) 1.93 (0.915-3.60) 8.09x10-2 
Missense - Motor Domain 3 (0.26%) 18 (0.09%) 3.27 (0.86-9.25) 7.74x10-2 
Missense - Microtubule Binding Domain 2 (0.18%) 8 (0.04%) 5.07 (0.95-18.52) 5.57x10-2 
Missense - Coiled-Coil Domain 3 (0.26%) 55 (0.28%) 1.01 (0.28-2.60) 9.83x10-1 
Missense - C-Terminal Domain 3 (0.26%) 7 (0.04%) 7.23 (1.74-24.55) 9.41x10-3 
Loss of Function 6 (0.53%) 3 (0.02%) 32.07 (9.05-135.27) 5.55x10-7 
Loss of Function (Including Frameshifts) 8 (0.70%) 3 (0.02%) 41.16 (12.61-167.57) 3.77x10-9 
 
 
 
 
 
